Shown solid blue (Tier 1) on the CMS 2025 OPO Tier Status map based on 2023 performance data; OPO name and code MOMA confirmed in the document's OPO code table.
This OPO is graded Tier 1 (2025 (data year 2023)) under the CMS Conditions for Coverage outcome measures. Tier 1 is the top-performing band, automatically recertified.
Mid-America Transplant: $108.1M revenue, $133.5M assets (FY2024 Form 990)
Mid-America Transplant Services (St. Louis OPO; EIN 23-7426306)
Per its fiscal-year-2024 IRS Form 990 (extracted on ProPublica Nonprofit Explorer), Mid-America Transplant Services, the OPO serving parts of Missouri, Illinois and Arkansas, reported total revenue of $108,143,652 and total assets of $133,538,293. Revenue rose from $82.5M (FY2022) to $95.6M (FY2023) to $108.1M (FY2024).
OPOs hold board seats and reported financial stakes in tissue processors (per reform-group analysis of OPO 990s)
AlloSource board (executives from Donor Alliance, Iowa Donor Network, Mid-America Transplant, ConnectLife, Gift of Hope); MTF Biologics board (Midwest Transplant Network, LifeShare of Oklahoma, New Jersey Sharing Network)
A published analysis by Organ Donation Reform (costlyeffects.organdonationreform.org), citing the OPOs' own IRS Form 990 filings on ProPublica, states that executives from five named OPOs sit on AlloSource's board and that these OPOs hold ownership stakes in AlloSource ranging from $8 million to $26.4 million, and that executives from three additional named OPOs sit on the MTF Biologics board. This is an advocacy-group compilation derived from public 990 data, not a government finding; the underlying per-OPO 990 figures should be independently confirmed.
Several OPOs hold multimillion-dollar equity stakes in a nonprofit tissue processor (AlloSource), per 990s
Donor Alliance, Iowa Donor Network, Mid-America Transplant, ConnectLife, Gift of Hope (re: AlloSource, EIN 84-1327507)
A reform-advocacy review citing the organizations' IRS Form 990 filings (via ProPublica) reports that five OPOs — Donor Alliance, Iowa Donor Network, Mid-America Transplant, ConnectLife, and Gift of Hope — hold equity stakes in AlloSource ranging from about $8 million to $26.4 million, with executives from those OPOs sitting on AlloSource's board.
Every item is institution-level public record, source-linked; no patient, donor, or family is named. A Tier or finding here repeats the government's own assessment of an organization holding a public monopoly. Back to OrganWatch.